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1. Introduction 
The World Health Organization, WHO, reported in 2010 that there were approximately 490 
million (7%) of people suffering from mental disorders, such as abuse of alcohol and other 
substances, major depression, bipolar disorder, schizophrenia and dementia, recommending 
research the pathophysiology of these disorders in order to improve their understanding 
and to develop more efficient and cost-effective interventions (WHO 2001, 2005). 
The diagnosis of mental disorders, should be based on objectively measurable parameters 
and, also, should help us to establish therapeutic guidelines, based on the etiology of the 
diseases, and their adaptation to each individual. The absence of an objective biological test 
for the diagnosis of mental disorders which would constitute the Gold Standard for this 
task, along with the frequent psychiatric comorbidity, heterogeneity and, polygenic and 
multifactorial etiology, requires the search for Biomarkers that facilitated the diagnosis and 
treatment of the psychiatric illnesses. The Convergent Functional Genomics has revealed 
that proteins, compounds of biochemical nature related to different physiological functions, 
genetic tests for diagnosis or, even, different functional tests such as, for example, the 
dexamethasone suppression test, DEX, used to study the function of the hypothalamic-
pituitary-adrenal axis, HPA, can be candidates (Avissar & Schreiber 2003; Kemperman 2007; 
Russell 2004).  
The use of Biomarkers, that is, a physical characteristic, or a biochemical or biological 
parameter, objectively measurable and quantifiable, that report the evolution and condition 
of certain normal physiological processes or pathological, or response to a therapeutic 
intervention, pharmacological or otherwise, is relatively new but this field has gained much 
interest in recent decades among clinicians and researchers. A Biomarker, as a measurable 
biological entity that points the presence or absence of a disease, a toxin, a biological 
condition, a genetic pattern, or a therapeutic response to a drug, must be related 
quantitatively with the disease progression and/or therapy (http://www.gaba-
network.org; Biomarkers Definitions Working Group, BDWG, 2001). 
Biomarkers, are utilized in psychiatry not only as tools that aid us in the diagnosis and 
treatment of various diseases, facilitating the use of therapies aimed at specific groups or 
individuals, but also, as Surrogate Markers or Clinical Surrogate Endpoints for PK, PD and 
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PG modelling in drug response, and to investigate the biological mechanisms of action and 
the efficacy and safety profile of the target drug, being this last point developed along this 
chapter (Riggs 1990).  
The search of a Biomarker begins with the selection of the groups of patients and controls, 
continous with the selection of the type of sample to use and, finally, the selection of the 
statistical analysis that allowed us to demonstrate differences between both groups, such as 
the multivariate analysis of cross-sectional data and multivariate correlation analysis of 
longitudinal data, so that, there was clear evidence that these Biomarkers are able to 
distinguish between controls and affected individuals. To complete the validation, we have 
to check this on a large group of patients following Food and Drugs Administration 
guidelines (FDA 2008). In the case of Biomarkers used to monitor pharmacological 
therapies, the choice and validation of these should be supported, in addition, on studies of 
the etiology of the disease being treated and mechanism of drug action, as well as provide 
data on its cost-effectiveness and its side effects (Kemperman 2007). 
In the other hand, a Surrogate Marker, defined as a laboratory measurement, physical sign 
or symptom, is used in therapy as a direct measure of how patient feels, functions, or 
survives and is expected was able to predict the effect of a treatment, ie, it is a test that is 
used as measure of the effect of a given specific treatment. It is a candidate Biomarker if it 
can be validated, taking this atribute when the evidence has proven that the predicted effect 
induced by drugs or other therapy, on the Surrogate Marker, produces the outcomes desired 
on the clinical characteristic of interest, such as blood pressure, serum cholesterol, 
intraocular pressure, etc, while Clinical Surrogate Endpoint refers to the final desirable 
value that we want to achieve for a specific Surrogate Marker, which is related to the level of 
disease progression, intensity of a symptom or sign, or a laboratory test, that constitute the 
desired target and that reflect the expected clinical outcome (BDWG 2001). 
To validate a Surrogate Marker as a Biomarker, we need to understand the biological 
relationship between the Surrogate Marker that predicts the desired clinical benefit and the 
clinical outcome achieved. For pharmacological treatments, we have to know, moreover, all 
therapeutic actions, if we want to conclude that the effect obtained on the Surrogate Marker 
will result in the beneficial clinical outcomes desired. (Buckley & Schatzberg 2009; Russell 
2004). 
In short, at the present time the biological causality of most psychiatric illnesses and the 
intimate mechanism of action of most psychotropic drugs are unknown. However, it is 
possible to modulate pharmacologically a large number of neuroreceptors, using this tool as 
target of drug therapies and utilizing to control of psychiatric disorders symptoms. We will 
review in this chapter, the role and potential use of Biomarkers and / or Surrogate Markers 
to optimize the pharmacological treatments of most common psychiatric illnesses, with 
emphasis on schizophrenia and depression, in order to use them in the dosage regimen 
calcualtion and choosing a particular therapeutic drug strategy (Noll 2006; Shaheen 2010). 
2. Models for therapeutic drug monitoring  
After the administration of a drug, several processes occur leading to the pharmacological 
effect, so that we can define Pharmacokinetics, PK, as "what the body does to a drug" and 
pharmacodynamics, PD, as " what the drug does to the body " (Geldof 2007).  
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There are three unitary models for the therapeutic drug monitoring: 
1. Pharmacokinetic models, PK. They are used to describe control processes of drug 
concentration in biological fluids at any time after its administration, being absorption, 
distribution, metabolism and excretion, the main stages that determine the evolution of 
the drug concentration versus time, so the PK-models, determine the overall course of 
the process (Perez-Urizar 2000). 
2. Pharmacodynamic models, PD. They are used to describe the relationship between the 
drug concentration and/or active metabolites and the magnitude of the 
pharmacological effect obtained such as, eg, blood pressure, heart rate, etc (Geldof 2007; 
Holford & Sheiner 1981; Rowland & Tozer 1995; Sheiner et al 1997) .  
3. Pharmacogenetic models, PG. They are used to describe the influence of interindividual 
genetic variations in the response to a drug in terms of efficacy and safety. They use 
genotype-phenotype, gene-concentration and gene-dose correlations for predicting the 
phenotype of a individual and provide support to achieve a optimal pharmacotherapy. 
As important part of the construction of these models, a Surrogate Marker or Biomarker is 
defined as measure that characterizes, in a strictly quantitative manner, the various 
processes and stages that occur between the administration of a drug and its 
pharmacological effect, and can be used in clinical practice for the individualization of drug 
therapy, from the viewpoint of dosage regimen calculation and therapeutic strategy. In fact, 
there is a growing interest in the use of biomarkers in drug development, as is reflected in 
the publication of numerous reviews and comments, appeared recently, on this topic. As 
well as, the recent increase in the number of publications about PK-PD models in journals of 
Clinical Pharmacology and Clinical Pharmacy, concerning to theoretical models and their 
implementation. Despite the continued increase in the number of articles, there are still, a 
large number of publications that contain pharmacokinetic and pharmacodynamic data 
without PK-PD modeling studies (Francheteau 1993; Geldof 2007; Mandem & Wada 1995; 
Zuideveld 2001).  
Optimization of pharmacologic treatment is usually done by monitoring serum drug 
concentrations, in PK models, or by the direct or indirect pharmacological response, 
represented by Biomarkers or Surrogate Markers, in PD models, combined with 
pharmacogenetic and environmental characteristics, in PG models.  
PK models can be non-parametric or compartimental. Non-parametric models provide an 
empirical description of the temporal evolution of drug concentration in terms of the 
maximum concentration, Cmax, and time needed to reach it, Tmax, and area under the 
concentration versus time curve, AUC. While compartmental models provide a description 
of concentration profile versus time of the drug in a body fluid compartment (Csajka & 
Vérotte 2006; Geldof 2007; Holford & Sheiner 1982; Perez-Urizar et al 2000).  
Binary models PK-PD, PK-PG and PD-PG, as a result of the union of simple models, are 
aimed to find out the suitable therapeutic dose, body "clearance" and other kinetic 
parameters related to plasma drug concentration or pharmacological effect, establish an 
adequate dosage scheme to achieve the desired therapeutic goal, as well as know the time 
evolution of the pharmacological effect, using the appropiate model and the individual 
genotype of the different populations to which treatment is targeted, by using the following 
mathematical tools: 
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1. General equation of the dose-response relationship, receptor mediated, which relates 
the intensity of the pharmacological effect, E, with the concentration of the drug, D, and 
of the receptor, R, presents in the body:  
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Once the steady-state and a pharmacological response, ranging between the 20-80% of 
maximal effect, is reached we can estimate the optimal dose required to achieve the desired 
Clinical Surrogate Endpoint, using the following expression, an approximation of the 
equation 1: 
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Where [ΔCSE]1 is the Clinical Surrogate Endpoint of the drug, equivalent to the average 
increase (delta, Δ) value obtained for CSE in the patients drug treated, [Δ CSE]2  is the 
experimental delta value obtained for CSE in a individual, (DD)2 is the dose of drug with 
which has been obtained a  [Δ CSE]2 value equal to 10 and (DD)1 is the drug target dose 
(Lozano et al 2007,2008a,2008b, 2009b,2010a,2010b,2010c, 2011a). 
2. Hill`s equation, equation 3, a partial solution of the above equation 1, from which 
comes, which relates the intensity of the pharmacological effect, E, on the Biomarker 
with the concentration of drug in the body, C, (Hill 1910): 
 max
50
C E
E
C EC

      (3) 
3. Kernel density estimation, Kernel`s test, used for poblational analysis, performed in the 
PK-PG and PD-PG models, which incorporate pharmacogenetic analysis (Wessa 2008).  
4. Finally, for interaction-based models, where two or more drugs that interact on the 
same receptor, the following equation, equation 4, serves to describe the relation 
between the reaction velocity, dV/dC, of a drug, A, with the receptor, , versus to that of 
another drug, B, on the same receptor: 
 
d dVa Vb
d dCa Cb
     (4) 
(Lozano et al 2009a, 2009c, 2010d). 
2.1 PK-PD models 
Consist of mathematical expressions that describe the quantitative relationships between the 
response intensity of a Biomarker or Surrogate Marker and drug dose applied. They have 
three components: a PK model, which characterizes the temporal evolution of the 
concentration of the drug and/or active metabolites, in blood or plasma, a PD model that 
characterizes the relationship between a drug concentration and/or possible active 
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metabolites to the pharmacological effect, and finally, an aggregate model that takes into 
consideration other factors that may affect the pharmacological effect, frequently observed 
in the models of compartmentalized pharmacological effect and in those of indirect 
pharmacological response (Breimer & Danhof 1997; Geldof 2007). 
The PK-PD models, can be: 
1. Mechanistic-based models, which characterize the time course of drug effect, “in vivo”, 
using expressions that describe the biophase drug distribution, target-drug binding, 
target-drug activation and feedback homeostatic processes and contain elements 
corresponding to the distribution in the target site , target-drug binding, and activation 
and transduction. They are based on the principles of receptor theory, that characterizes 
the interaction of the receptor with the drug in terms of affinity and intrinsic activity. In 
these models, PK-PD, when steady-state is reached, drug concentration in the biophase 
is paralell to the plasma concentration and directly proportional to the dose (BDWG 
2001; Geldof 2007; Sheiner et al 1979 Van der Graaf & Danhof 1997). 
Under stable conditions, relatively simple models, such as those linear or log-linear, can be 
used to characterize the dose-response relationship. The most used is the sigmoid model, 
which is an empirical function to describe the nonlinear relationship between drug 
concentration and the pharmacological effect; this model is mathematically expressed by the 
general equation for dose-response curve, equation 1, or also by Hill`s equation, equation 3, 
a partial solution of the previous, where E is the pharmacological effect observed with a 
given dose , E0 is the response in the absence of drug, Emax is the maximum effect or intrinsic 
activity of drug, C is the concentration of drug and/or metabolite in plasma and/or 
biophase, EC50 is the concentration of drug and / or metabolites that produce 50% of 
maximal effect, potency, and γ is the Hill factor, that expresses the sigmoidicity of the curve 
(Geldof 2007; Hill 1910; Holford & Sheiner 1982; Meibohm & Derendorf, 1997). 
Under conditions of non steady-state , the basic models PK-PD are unable to describe the 
time evolution of the pharmacological effect. Factors such as the compartimiental effect, 
acute tolerance and sensitization, and indirect response modeling, can explain the 
dissociation, frequently observed, between the temporal evolution of the drug concentration 
and pharmacological effect, using, in these cases, the previous model but applied to 
different doses to simulate the change in concentration along the time (Bauer et al 1997; 
Dayneko et al 1993; Derendorf & Meibohm 1999; Jusko & Ko 1994; Ragueneau et al 1998; 
Sheiner et al 1979).  
2. Indirect response models, are based on a combination of the inhibitor or stimulant 
effect, that can produce the drug, and the factors controling the increase or decrease of 
the pharmacological response, represented by the constants Kin and Kout (Derendorf & 
Meibohm 1999, Mager et al 2003; Meibohm & Derendorf 1997; Rowland & Tozer 1995). 
3. Drug interaction-based models, are used to describe the influence of two or more drugs 
among them, acting on the same receptor. Their use are limited to situations in which 
several drugs are administered together, or when a drug becomes an active metabolite. 
In theoretical terms refer to the prediction of the combined effects of more than one 
drug. The general approach to the study of these interactions involves the analysis of 
changes in the velocity of reaction that occur when the drugs are used combined or 
separately (Lozano et al 2009a, 2009c, 2010d). 
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4. Poblational models, are used to solve the problem of inter and intra-individual  
variability in the therapeutic response to a drug. In PK and PD models, the kinetic 
parameters of each individual are modeled in terms of the fixed effect observed, and 
other of random nature, while PK-PD poblational models, based on nonlinear mixed 
effects analysis, characterize the pharmacokinetic parameters and concentration-effect 
relationship, in poblational terms more than individual. Thus, in PK and PK-PD 
poblational models, we need to know in advance the average behaviour of 
pharmacokinetic parameters in target population, to identify and assess demographic, 
pathophysiological and environmental factors, affecting population under study and, 
finally, evaluate the inter and intraindivual variability through the variation coefficient 
of the PK parameters and their residual components (Dominguez-Gil & Lanao 1999; 
Schnider et al 1996). 
2.2 The PK-PG models  
Consist of mathematical expressions that describe the quantitative relationship between the 
drug dose necessary to achieve the same response intensity of a Biomarker or Surrogate 
Marker, for each one of the different genotypes phenotypically actives present in a 
population. 
Pharmacogenetic models, PK-PG, are used to adapt the therapeutic use of different drugs to 
the idiosyncrasy of each patient and their genetic characteristics, increasing its efficiency and 
minimizing their side effects. Approximately 20-90% of the interindividual variability in 
drug response is consequence of individual genotype and variants that encode different 
polymorphs of the enzymes that metabolize and / or transport drugs.  
Single Nucleotide Polymorphisms, SNPs, have been associated with substantial changes in 
the metabolism or in the effect of a drug, and therefore are being used to predict the clinical 
response to a drug of an individual. For the biotransformation of a drug, there are over 30 
families of metabolizers enzymes belonging the family of cytochrome P-450, whose genetic 
polymorphisms normally lead to a functional changes in the encoded protein, resulting in 
individuals with different phenotypes: 
a. Poor Metabolizers, PM: The encoded enzyme has no activity, the metabolic activity is very 
reduced or absent and the phenotype is predicted by the presence of two inactive alleles. 
b. Intermediate Metabolizers, IM: The encoded enzyme has its activity decreased, the 
phenotype is predicted by the presence of two alleles with decreased activity, or a 
combination of a reduced activity allele and a allele with no activity.  
c. Extended metabolizers, EM: They are carriers of one active gene copy at least, have a 
normal metabolic activity and phenotype is predicted from the combination of two 
active alleles. For some genes, the presence of one active allele combined with one allele 
with decreased activity or allele with no activity, causes that the metabolic activity was 
normal.  
d. Ultrafast Metabolizers, UM: They have a double metabolic capacity and the phenotype  
is predicted by the presence of three or more functional alleles or the presence of two 
inducible alleles http://cpmc.coriell.org/Sections/Medical/DrugsAndGenes_mp 
.aspx?PgId=216). 
Carrier proteins of drugs play an important role in regulating the absorption, distribution 
and excretion of many drugs. Within the ATP-binding cassette family, P-glycoprotein, 
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encoded by the ABCB1 gene, is one of the best known , being its main function the control of 
the outflow from inside the cells of certain endogenous and / or exogenous substrates, 
including several drugs and substances such as bilirubin, so the presence of polymorphisms 
in this gene, entails changes in the PK and PD of certain drugs. 
2.3 The PD-PG models  
PD-PG models, consist of mathematical expressions that describe the quantitative relationship 
between the response intensity of a Biomarker or Surrogate Marker, to a single dose of the 
drug, and the different genotypes phenotypically actives present in a specific population. 
Pharmacogenetic models, PD-PG, are used to adapt the therapeutic use of different drugs to 
the idiosyncrasy of each patient and their genetic characteristics, increasing its efficiency and 
minimizing their side effects. Approximately 20-90% of the interindividual variability in 
drug response is consequence of individual genotype and variants that encode different 
polymorphs of therapeutic targets.  
Genetic polymorphisms with indirect effects on the response to drugs are those that affect to 
a genes encoding proteins that often are involved in the mechanisms of the drug disposition, 
producing alterations in the response to treatment only under certain situations. 
Therefore, both PK -PG and PD-PG models are used to describe the genotype-phenotype, 
gene-concentration and gene-dose correlations, necessary to achieve an optimal 
pharmacotherapy (Brockmöller & Tzvetkov 2008, Tsai & Hoyme 2002; Weinshilboum & 
Wang 2006). 
3. Biomarkers for therapeutic drug monitoring in psychiatry 
3.1 Lithium 
Bipolar disorder, BD, is characterized by the presence of one or more episodes of mania or, 
in mild cases, hypomania and additional depressive episodes, concomitants or alternants. 
The cause is unknown, although recent studies suggest the presence of an imbalance 
between excitatory neurotransmitters, mainly glutamate, and inhibitors, principally GABA, 
as well as alterations in cation pumps, such as of sodium and of calcium, which would 
explain the pathogenesis of bipolar disorder and another pathologies as epilepsy (Brown & 
Sherwood 2006). 
To explain the action mechanism of Lithium salts there are several proposals, being the most 
known: 
1. Inhibition of the enzyme GSK-3B, whose complete mechanism in relation with BD has 
not yet been hypothesized (Jonker et al 2003). 
2. Blockade of the NMDA/ NO receptor: The Nitric Oxide, NO, plays a crucial role in 
neuronal plasticity, having shown that the NO system may be involved in the 
antidepressant effect of lithium amd the increase in antidepressant capacity of lithium 
by the blockade of NMDA receptor would indicate an involvement of the NMDA/NO 
receptor in the pharmacological action of lithium (Ghasemi et al. 2008, 2009a, 2009b; 
Ghasemi & Race 2008). 
3. Inhibition of Inositol monophosphatase enzyme (Einat et al 1998). 
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All the pharmacological activity of lithium salts is carried out by the insolubilization of 
intracellular inorganic phosphate salts through the formation of inorganic lithium 
phosphates. These ones have much lower solubility than their sodium salts (eg the solubility 
of Li3PO4 in water is 0.03821 g/dL/20 ° C versus of the Na3PO4 that is 8.8 g/dL/25 º C), 
which leads to decrease the amount of intracellular inorganic soluble phosphates, Pi, 
causing, consequently, decrease in intracellular phosphate stored in organic compounds, Po, 
and slowdown all metabolic reactions that involve exchange of inorganic phosphates, 
mainly those using ATP but, also, those using another nucleotides with capacity for the 
storage of phosphates, as we know now , and affecting in a hierarchically manner to several 
intracellular pathways of activation and/or inhibition, being those of GSK and inositol-
phosphates, among other, the first to be affected (Lozano et al 2009a, 2010a,2010b). 
In the case of the thyroid gland, lithium salts cause a dose-dependent decrease in serum free 
thyroxine, FT4, due to the very low solubility of inorganic lithium phosphates, formed in the 
interior of target cells by action of lithium, which leads to a decrease in the intracellular pH 
and in the tyrosine iodination reaction, pH dependent, with consequent decrease of the FT4 
levels, because the iodination of phenols is a direct reaction of iodine, I2, on the phenolate 
ion, very sensitive to changes in pH, decreasing exponentially the rate of iodination when 
the pH does it (Kessler et al 2008; Lozano et al 2010a, 2010b; Taylor & Evans 1953). 
3.1.1 PK-PD model 
Mechanistic-model. We can use the FT4 levels in plasma as a biomarker for quantifying the 
intraneuronal concentration of Lithium and the dosage regimen calculation in the 
treatments of bipolar disorder with salts Lithium, increasing o decreasing the daily dosage 
to reach FT4 values, in the range of 1.02-1.08 ng/dL, its Clinical Surrogate Endpoint (Lozano 
et al 2010a, 2010b).  
3.1.2 PK-PG model 
Due to the Lithium elimination by glomerular filtration, the poblational analisys conducted 
by Kernel`s test has allowed us to detect two subpopulations related to serum creatinine and 
therefore with the Lithium Clearance, caused by the presence of MDR1 polymorphisms, 
altering the aldosterone level and therefore the Creatinine Clearance, obtaining from the 
application of the equation 2, the following equi-effective dose ratio: 
 
 
DOSE genotype:wild type
1.5 2
DOSE genotype:polimorphic type
   
(Lozano et al 2011b).  
3.1.3 PK-PG model 
Poblational analysis conducted by Kernel`s test has not detected any subpopulation. 
3.2 Escitalopram-SSRI  
Depression is a pathological alteration of mood, being Major Depressive disorder the most 
studied with a prevalence of 10-25%. Its complex origin, is attributed to a defective 
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transmission of noradrenaline and dopamine associated with dysregulation of the 
hypothalamic-pituitary-adrenal axis , HPA, which is reflected by the alteration of the 
cortisol escape from suppression by dexamethasone in the Dexamethasone Suppression test, 
DEX test, and by the increased response of cortisol in the Dexamethasone-Suppressed 
Corticotropin-Releasing Hormone Stimulation Test, DEX-CRH test. The decrease in 
serotonergic transmission in the brain and increased secretion of cortisol in patients with 
major depression have reached the status of an axiom in textbooks, being the cortisol the 
biological key mediator through which the brain slows down serotonergic transmission that 
causes depression in vulnerable people (American Psychiatric Association 2000; Dinan, 
1996; Goodwin & Post 1983; Noll 2006; Schnider et al 1996). 
Deregulation of the hypothalamic-pituitary-adrenal axis is present in a high rate among the 
patients with depression and its normalization, observed by the response to the DEX-CRH 
test, is verified when there is a good response to pharmacological treatment. Moreover, the 
serotonergic system interacts with the hypothalamic-pituitary-adrenal axis and, because of 
this, the stimulation of this axis can be used as a Surrogate Marker for the pharmacological 
action of the 5-HT agonist in the CNS (Cowen 1993, 1998; Gartside & Cowen 1990; Meltzer & 
Maes 1994; Meltzer et al 1991). 
The reduced serotonergic neurotransmission is well known feature of the depression and 
therefore it is not surprising that SSRI drugs were the first line of treatment in depressive 
disorders. Plasma levels of Escitalopram and another SSRI drugs decrease the HPA-response 
in the DEX test and there is a good correlation between dose of the SSRI drug and decreasing 
of plasma cortisol. Cortisol values obtained by Nugent's test, can be used as a Biomarker or 
Surrogate Marker for dosage regimen calculation of antidepressant drugs that act on 
serotonergic regulation of the HPA axis. The SSRI drugs whose main action is the activation of 
serotonergic transmission, produce a decrease of plasma cortisol value obtained by Nugent`s 
test, in dose-dependent manner and can be used as surrogate marker of SERT-carrier 
occupation and 5-HT receptor activation by the Escitalopram and/or other SSRI drugs and to 
serve for their dosage regimen calculation (Bel & Artigas 1992; Berkenbosch et al 1987; Bosker 
et al 1994; Hsieh et al 2010; Ising et al 2005, 2007; Knorr et al 2011; Maes et al 1993; Meltzer 
1985; Nordstrom & Farde 1998; Sasayama et al 2011; Schule et al 2009). 
3.2.1 PK-PD model 
PK-PD mechanistic-model. Around 50-60% of patients with depression have an increased 
activity of the hypothalamic-pituitary-adrenal axis and altered its regulation by negative 
feedback. Escitalopram and other SSRI produce an up-regulation of CRH receptors in a 
dose-dependent manner that can be measured by Nuggent`s test and this can be used for 
dosage regimen calculation of escitalopram and other SSRIs.  
Once the steady-state and a pharmacological response, ranging between the 20-80% of 
maximal effect, is reached we can estimate the optimal dose required to achieve cortisol 
values of 9.0 ± 2.1 mcg/dl, its Clinical Surrogate Endpoint, using equation 2 (Lozano et al 
2008a, 2011a). 
3.2.2 PK-PG model 
Metabolic studies for Escitalopram /Citalopram indicate that CYP3A4 and CYP2C19 are the 
major isozymes involved in N-demethylation of Escitalopram /Citalopram. The alleles 
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CYP2C19 * 2, CYP2C19 * 3 and CYP2C19 * 17 CYP2C19 and their combinations lead to 
phenotypes PM and IM, obtaining from the application of the equation 2, the following 
equi-effective dose ratios: 
 
 
DOSE CYP2C19 phenotype : EM
2
DOSE CYP2C19 phenotype : IM
  and  
 
 
DOSE CYP2C19 phenotype : EM
4
DOSE CYP2C19 phenotype : PM
  
Paroxetine, Fluoxetine and Sertraline, which are metabolized by the CYP2D6 whose activity 
ranges considerably within a population and includes Ultrafast metabolizers, UM, Extensive 
metabolizers, EM, Intermediate metabolizers,IM, and Poor metabolizers, PM. Among these 
are fully functional alleles, alleles with reduced function and null, non-functional, alleles, 
which convey a wide range of enzyme activity, from no activity to ultrarapid metabolism of 
substrates. Null alleles of CYP2D6 do not encode a functional protein and have no 
detectable residual enzymatic activity, being responsibles for the PM phenotype in 
homozygous and for IM phenotype in heterozygous, when to present (Zhou 2008), 
obtaining from the application of the equation 2, the following equi-effective dose ratios: 
 
 
DOSE CYP2D6 phenotype : EM
2
DOSE CYP2D6 phenotype : IM
  and  
 
 
DOSE CYP2D6 phenotype : EM
4
DOSE CYP2D6 phenotype : PM
  
(Lozano et al 2008a). 
3.3 Antipsychotics 
Schizophrenia first described by Benedict Morel in 1853 and with a prevalence of 1% in the 
general population, represents a group of chronic and severe mental disorders. Although its 
origin is unknown, there is an increased dopaminergic activity in the mesolimbic pathway 
of the brain. This biochemical alteration is used as target for the drug treatment of this 
disease, being the blockade of dopamine D2 receptors in the limbic system important for the 
control of the psychotic symptoms and the blockade of 5HT2a receptor for the control of 
negative symptoms. 
Despite the unknown action mechanism of antipsychotic drug, is known that all of them act 
on the dopaminergic system but their affinitiy for dopamin and serotonin receptors,D2 and 
5-HT, are different, being necessary the blockade of these receptors for its pharmacological 
action, being the combined blockade of the receptors 5-HT2a and D2 a method that evidence 
has proposed for the treatment of schizophrenia (Horacek et al 2006). 
Prolactin plasma level, PRL, reflects the tuberoinfundibular D2 blockade and can be used as 
a Biomarker or Surrogate Marker for drugs affecting dopaminergic system and, in general, 
for atypical antipsychotics which main action was the blockade of D2 receptors, since they 
produce a dose-dependent prolactin increase that can be used as a surrogate for D2 receptor 
occupation and to serve at the same time for the dose adjustment and/or, by extension, the 
absence of prolactin increase levels after antipsychotic treatment could be considered a 
surrogate of a decrease occupancy of the D2 receptor, as for Aripiprazole. Eventually, low 
occupancy of D2 receptors in the striatum can be used as Surrogate Marker for the 
likelyhood of motor side effects (Avrantis & Miller 1997; Kapur et al 2000; Meltzer 1985; 
Nordstrom & Farde 1998).  
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Prolactin plasma levels are also high in several drug treatments, such as: (a) Those that are 
expected to increase extracellular 5-HT levels in the brain as L-tryptophan, and 5-
hydroxytrytophan, (b) those that acting stimulating different types of 5HT receptors, and 
some, but not all, 5HT1a selective agonists. In all these cases, prolactin plasma level becomes 
a surrogate of the increase of serotonergic transmission in one or more regions of the brain. 
The blockade of this effect, by an antagonist drug of the 5-HT receptors, appropriate and 
specific, can serve, in turn, as a substitute for the ability of a drug for the functional 
antagonization of the receptor (Goddard 1993; Golden et al 1989; Murphy et al 1996;; Seibyl 
et al 1991; Seletti et al 1995; Silverstone & Cowen 1994). 
3.3.1 Risperidone  
Risperidone, an atypical antipsychotic with high affinity for dopamine receptors D2 and 
Serotonin 5-HT2a, produces a dose-dependent D2 receptor occupancy in the mesolimbic 
system, necessary for the control of the disease, while the blockade in the nigrostriatal 
would be responsible for extrapyramidal side effects and in the tuberoinfundibular of the 
hiperprolactinemy. 
3.3.1.1 PK-PD model  
Mechanistic-model. Risperidone produces a blockade of D2 receptor in the 
tuberoinfundibular system causing a dose-dependent increase in prolactin that can be used 
for dosing it. Using the values of serum prolactin, obtained in the morning before 
administration of Risperidone and not before steady-state plasma levels , minimum 
concentration in "steady-state", are reached we can construct the dose-response curve of 
prolactin plasma level versus Risperidone dose, which fits a rectangular modified 
hyperbola, equation 5, and permit us to establish a maximum value of PRL= 80-90 (40-45) 
ng/ml and a minimum value of PRL= 40-50 (20-25) ng/ml, for the optimal dose of 
risperidone, in women and men, in parentheses (Lozano et al 2007, 2010c): 
  
2
2
84
90
Risp
PRL
Risp   (5) 
3.3.1.2 PK-PG model 
Risperidone is eliminated by metabolism mainly through the action of citochrome CYP2D6, 
and to a lesser extent through CYP3A4. Risperidone and its main metabolite, 9-OH-
risperidone, constitute the "active fraction" with an elimination half-life of 6 and 24 hours, 
respectively, in extensive metabolisers, EM, and 20 and 30 h in the case of patients with 
phenotype "poor metabolizer" PM. The "clearance", Cl, for the active fraction of Risperidone 
is respectively of 5.0 and 13.7 l/h in EM subjects and 3.2 and 3.3 l/h in individuals PM 
(Janssen Research Foundation 1994). 
The CYP2D6 activity ranges considerably within a population and includes Ultrafast 
metabolizers, UM, Extensive metabolizers, EM, Intermediate metabolizers,IM, and Poor 
metabolizers, PM. Among these are fully functional alleles, alleles with reduced function 
and null, non-functional, alleles, which convey a wide range of enzyme activity, from no 
activity to ultrarapid metabolism of substrates. Null alleles of CYP2D6 do not encode a 
functional protein and have no detectable residual enzymatic activity, being responsibles for 
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the PM phenotype in homozygous and for IM phenotype in heterozygous, when to present 
(Zhou 2008), obtaining from the application of the equation 2, the following equi-effective 
dose ratios: 
 
 
DOSE CYP2D6 phenotype : EM
1.5
DOSE CYP2D6 phenotype : IM
   and  
 
 
DOSE CYP2D6 phenotype : EM
3
DOSE CYP2D6 phenotype : PM
  
(Lozano et al 2007, 2010c). 
3.3.1.3 PD-PG model 
The poblational analysis of PRL values, using Kernel`s test, allowed us to detect two 
subpopulations, sex-linked, and related to an alteration of the dopaminergic and / or 
serotonergic pathways, caused by a combination of polymorphisms of the genes encoding 
receptors 5-HT2a , D2, and SERT, among others, obtaining from the application of the 
equation 2, the following equi-effective dose ratio: 
 
 
DOSE genotype :  wild type
0.4 / 2.5
DOSE genotype :  polimorphic type
  
in men and women, respectivily (Lozano et al 2007, 2010c). 
3.3.2 Clozapine and olanzapine 
Since the HPA axis regulation appears altered in patients with schizophrenia, its modulation 
may be relevant for the control of symptoms in schizophrenia and antipsychotic treatment 
response. Otherwise, cortisol can be used as surrogate of the 5HT2a receptor blockade, the 
receptor that has manifested itself as the most important in the serotonergic regulation of 
HPA axis and, thus, can be used as Surrogate Marker for dosing antipsychotics that act 
predominantly on the serotonergic pathways (Marx & Lieberman 1998; Meltzer et al 2001; 
Morrow et al 1995). Moreover, the alteration of the HPA axis, induced by antipsychotic with 
capacity for serotoninergic antagonism, that bind strongly to receptors 5-HT2a/2c, can be 
used to modulate the response of cortisol and, eventually, to suppress the axis and to cause 
a decrease of the corticotropin-releasing factor, CRF, and the adrenocorticotropin hormone, 
ACTH (Morrow et al 1995; Patchev et al 1994). 
Clozapine and Olanzapine, a 5HT2a antagonists, show strong affinity for some dopamine 
receptors, but weak ability to antagonize the D2 receptor, a receptor that modulates the 
neuroleptic activity. Evidence has shown that cortisol levels achieved in individuals treated 
with olanzapine and clozapine are dose dependent and directly proportional to the plasma 
concentrations of these drugs, at the start of antipsychotic treatment and along it.  
Not only Olanzapine and Clozapine have shown a dose-dependent effect on the plasma 
cortisol levels, Risperidone also has significant effects but less pronounced compared with 
Olanzapine and Clozapine, whereas, Haloperidol has more modest effects. Olanzapine and 
Clozapine produce a cortisol increases, Δ-delta, up to 4-5 times higher than those produced 
by Haloperidol, while, risperidone produces a cortisol increases almost 1.5 times greater 
than observed with Haloperidol. Therefore, antipsychotics dosage are suitable to be 
monitored by using cortisol plasma levels (Girdler et al 2001). 
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3.3.2.1 PK-PD model 
Mechanistic-model. Clozapine and Olanzapine, among other antipsychotics, cause an 
increase plasma cortisol levels in a dose-dependent manner, so the daily dosage has to be 
increased or decreased in order to reach cortisol plasma levels of 19.6 ± 6.6 mcg / dL and 
18.3 ± 5.3 mcg / dL, the Clinical Surrogate Endpoint for Clozapine or Olanzapine, 
respectively (Lozano et al 2007, 2008a, 2010c, 2011a). 
Once the steady-state and a pharmacological response, ranging between the 20-80% of 
maximal effect, is reached, we can estimate the optimal dose required to achieve cortisol 
values of 19.6 ± 6.6 mcg / dL and 18.3 ± 5.3 mcg / dL, the Clinical Surrogate Endpoints for 
Clozapine or Olanzapine, respectively, using equation 2 (Lozano et al 2008a, 2011a). 
3.3.2.2 PK-PD model  
Clozapine and Olanzapine are extensively metabolized in the liver, via the cytochrome P450 
system, to polar metabolites suitable for its elimination in the urine and faeces. The CYP1A2 
isoenzyme is primarily responsible for metabolism of Clozapine and Olanzapine , but 
another CYP`s seems to play a role, as well. Inducers agents, e.g. cigarette smoke, or 
inhibitor agents, e.g. Theophylline, Ciprofloxacin, Fluvoxamine, of the CYP1A2 may 
increase or decrease, respectively, the metabolism of Clozapine and Olanzapine. For 
example, the induction of metabolism caused by smoking means, that smokers would 
require double up the dose of Clozapine and/or Olanzapine compared with non-smokers ir 
order to achieve an equivalent plasma concentration (Entrez Gene 2011). 
3.3.2.3 PD-PG model  
The poblational analysis of plasma cortisol levels, using Kernel`s test , allow us to detect 2 
populations, sex-linked and related to an alterations of the dopaminergic and/or 
serotonergic, caused by a combination of the different polymorphisms of genes encoding 
SERT and 5-HT2a receptor, among others, obtaining from the application of the equation 2, 
the following equi-effective dose ratio: 
 
 
DOSE genotype : wild type
2 or 4
DOSE genotype : polimorphic type
  
in dependence of the variant alleles present (Lozano et al 2008a, 2010c). 
3.4 Methadone 
The reduction of the testosterone levels induced by drugs with opioid activity, seems to be 
receptor mediated, since the different isomers have different activities: the levorotatory 
isomers are much more effective than dextrorotatory isomers (Cicero et al 1974, 1975, 1976, 
1977; Mendelson et al 1976). 
There are many different studies showing that the relative potency of drugs to reduce serum 
testosterone levels is parallel to its analgesic activity and its affinity for opioid receptors in 
the brain. So, this ability to decrease plasma testosterone and/or urine can be used as a trial 
to evaluate the structure-activity relationship, kinetic constants of association-dissociation to 
receptors, and reach conclusions about their pharmacological potency and its optimal 
therapeutic dose (Cicero et al 1975, Mendelson et al 1976). 
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The ability of opioid drugs to reduce serum testosterone levels, also, can be effectively used 
as a measure to assess the pharmacological activity of Methadone. Therefore, indirect 
assessment of the Methadone concentration in the biophase, can be accomplished by using 
the test of depletion of testosterone or test of depletion of LH that, also, seems to be specific 
for narcotic effect and correlates well with changes in testosterone levels (Kosterlitz & Warp 
1968; Lozano et al 2008b, 2009b; Snyder 1975). 
3.4.1 PK-PD model 
Methadone, among other opiate drugs, causes a decrease in the value of index, 
testosterone/creatinine in urine, in a dose-dependent manner. We can dose Methadone by 
increasing o decreasing the daily dosage to reach index values of 20-30 mg / g, the Clinical 
Surrogate Endpoint. (Lozano et al 2008b, 2009b). 
Once the steady-state and a pharmacological response, ranging between the 20-80% of 
maximal effect, is reached we can estimate the optimal dose required to achieve its Clinical 
Surrogate Endpoint, using equation 2 
3.4.2 PK-PG model 
Poblational analysis of the index, testosterone/creatinine in urine, using Kernel`s test , have 
allowed us to detect 3 different populations, as a result of combination of the different 
polymorphisms affecting the genes that encode CYP3A, CYP2B6, and NAT2, obtaining from 
the application of the equation 2, the following equi-effective dose ratio: 
 
 
DOSE genotype : wild type
2 or 4
DOSE genotype : polimorphic type
  
in dependence of the variant alleles present (Lozano et al 2008b, 2009b). 
3.5 Lamotrigine 
Lamotrigine is a drug specifically used for epilepsy but also is effective as a mood stabilizer 
in treating bipolar depression, one of the most intractable stages of this disorder. Its 
iatrogenic effects, rare but extremely serious, such as Stevens-Johnson syndrome or Lyell 
syndrome, usually appear at 2-8 weeks of starting treatment. With unknown mechanism of 
action, it is believed that acts on sodium channels, its use is reserved for prevention of 
depressive episodes in bipolar disorder. 
Lamotrigine is eliminated from the body by the action of the UGT1A4 enzyme, competing 
with bilirubin for the formation of their respective conjugates with glucuronide acid. Taking 
advantage of this interaction over UGT1A4, we can use bilirubin plasma levels as a indicator 
of plasma Lamotrigine concentration (French 2004; Lees & Leach 1993; Pellock 1999; Ramsay 
et al 1991; Rogawski & Löscher 2004). 
The influence of bilirubin and other inhibitors of the UGT1A4 enzyme, on plasma 
concentrations of Lamotrigine, is calculated assuming a Michaelis-Menten kinetics, using 
equation 4, and a competitive inhibition model, as follows: 
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    2
Ltg Bilo M M
Bil
Ltg
E K K
 
  
  (6) 
(Eo = [UGT], KM = Michaelis-Menten Constant) 
(Bil= Bilirrubina, Ltg= Lamotrigina, Inh= Inhibidor) 
allowing us to conclude that the main factors affecting Cp of Lamotrigine are the amount of 
UGT enzyme (Eo) and KM values of inhibitors with respect to those of Lamotrigine and 
Bilirubin, according to the following relation: 
 
 
 
 
Inh
Ltg
M
M
KLtg
Inh K   (7) 
This method described above allows the analysis of the main factors affecting competitive 
inhibition between two substrates, such as: UGT enzyme concentration, exponentially, and 
KM value of substrates (Lozano et al 2009a, 2009b, 2010d). 
3.5.1 PK-PG model 
Is based on individual genetic polymorphisms which can alter the enzymatic activity of 
UGT1A1: The enzyme that conjugates bilirubin is called uridindifosfoglucuronato 
glucuronosyltransferase,UGT, and its production is regulated by a promoter that can have a 
mutation that causes decreased production of this enzyme. The amounts of UGT, in Gilbert's 
syndrome, are reduced until 30% of the normal value. The genetic defect is in the insertion 
of an extra base pair in the promoter TATA box in the gene encoding the enzyme UGT and 
that is located on chromosome 2 (Bosma et al 1995). Gilbert's syndrome, therefore, is a 
disease in which there is a high bilirubin level and the values in these patients ranging 
between 20 mmol/dl and 80 mmol/dl, obtaining from the application of the equation 6, the 
following equi-effective dose ratio for Lamotrigine: 
 
 
DOSE genotype : wild type
2
DOSE genotype : Gilbert`s syndrome
  
(Lozano et al 2009a, 2009c, 2010d). 
3.6 New antiepileptics 
The new generation of AEDs such as Topiramate, Oxcarbazepine, Gabapentin, and 
Levetiracetam, acts by enhancing GABAergic neurotransmission: The gamma-aminobutyric 
acid, GABA, has 2 types of receptors, A and B. When GABA binds to GABAA receptor, 
facilitates the passage of chlorine, negatively charged ion, inside the cell through chloride 
channels. This influx of chloride increases the negativity of the cell (ie, a resting potential 
more negative membrane) causing it a greater difficulty to reach the action potential 
resulting, finally, in a cell stabilization (Barnard et al 1998; Kravitz et al 1963; Krnjević & 
Schwartz 1967; Sieghart & Sperk 2002; Takeuchi & Onodera 1972; Takeuchi & Takeuchi 
1967, 1969). 
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The GABAergic transmission, may be increased or facilitated, by direct binding of an 
agonist, such as progesterone, benzodiazepines, barbiturates, to the GABAA receptors and 
its subsequent activation; by blocking the presynaptic uptake of GABA by Tiagabine; by 
inhibiting the metabolism of GABA by GABA-transaminase, such as Vigabatrin and 
Valproate, or by increasing GABA synthesis modulating the enzyme glutamic acid 
decarboxylase, GAD, responsible for the decarboxylation of glutamate to GABA, as is the 
case of Gabapentin and other AEDs that enhance the production of GABA and causes a 
down-regulation of glutamate. For Felbamate, whose exact mechanism is unknown, it is 
known that exerts its effect on the GABA receptor and by antagonizing the NMDA receptor, 
while, Topiramato locks the sodium channels of voltage-gated and increases the activity of 
GABA through the activation of some subtype of GABA receptors, antagonizing some 
subtype of glutamate receptor and inhibiting the enzyme carbonic anhydrase, particularly 
isozymes II and IV (Kapetanovic et al 1998; Kume al 1994). 
The GH plasma levels, also, have been used as a Surrogate Marker of noradrenergic 
transmission and, more recently, as evidence of 5HT1a and 5HT1b/d1 receptor activation, 
being this another example of how one Surrogate Marker serves as measure for very 
different effects in the CNS (Dinan 1996; Facchinetti et al 1994; Herdman et al 1994; 
Laakman al 1990; Mota et al 1997). 
3.6.1 PK-PD model 
The GH plasma levels, can serve as a Surrogate Marker for assessing the GABAergic 
transmission in the CNS and is therefore a useful tool for dosage regimen calculation of the 
new antiepileptic drugs and for the right choice of therapeutic strategy, since, the oral 
administration of drugs that facilitates GABAergic transmission, among them the 
antiepileptics, cause a rise of growth hormone plasma levels, GH, in a dose-dependent 
manner, being GH release induced by gamma-aminobutyric acid, GABA, and mediated by a 
dopaminergic mechanism, via dopamine release at suprapituitary level (Cavagnini et al 
1980a, 1980b; Powers et al 2008).  
Thus, eg, Diazepam administration causes a dose-dependent rise in GH and the reached 
plasmatic peak is related to the plasma level of the drug. This highly significant correlation 
of the serum concentrations, between GH and Diazepam, has been found, also, with other 
AEDs, that act via the release or facilitation of GABAergic transmission, so we can use the 
plasma levels of GH as a Biomarker for dose adjustment of Diazepam, Topiramate, 
Gabapentin, Oxcarbazepine, Valproate and Levetiracetam, being the optimal dose, that 
which allow us to achieve the Clinical Surrogate Endpoint of GH equal to 15-25 ng/ml 
(Monteiro et al 1990; Monteleone et al 1987; Syvälahti & Kanto 1975). 
Once the steady-state and a pharmacological response, ranging between the 20-80% of 
maximal effect, is reached we can estimate the optimal dose required to achieve the Clinical 
Surrogate Endpoint of GH equal to 15-25 ng/ml, using equation 2.  
4. Conclusion 
In this chapter, we have developed some PK, PD and PG models , in order to study and 
monitor the effectiveness, dosage regimen calculation and security of drugs used in 
psychiatry, by means of Biomarkers of drug concentration in biophase and the incorporation 
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of all the most innovative techniques in pharmacokinetics, pharmacodynamics and 
pharmacogenetics , which allow us to:  
1. Estimate their pharmacokinetic and pharmacodynamic parameters, using for this 
purpose, PK-PD, PK-PD and PG-PG modelling, and quantitative analysis of dose-effect 
relationships with mathematical covariant techniques. 
2. Quantify the effect of different genetic polymorphisms of CYP450, receptors and 
carriers, in dosage regimen calculation of different drugs above described. 
3. Identify, using Kernel`s test, the different phenotypes and subpopulations originated in 
the different dose-response and metabolic behavior, such as the EM, PM and UM 
phenotypes.  
In conclusion, the use of Biomarkers in PK, PD and PG modelling, in continuos developing, 
has provided us with the adequate tools to choose the best therapeutic strategy and 
calculate optimal dose, in order to improve the therapeutic drug monitoring of psychiatric 
drugs, relapses, drug side effects and clinical outcome of the most common psychiatric 
diseases. http://cpmc.coriell.org/Sections/Medical/DrugsAndGenes_mp.aspx?PgId=216.  
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